Evommune (EVMN) Profit After Tax (2024 - 2026)

Evommune (EVMN) has 3 years of Profit After Tax data on file, last reported at -$21.7 million in Q1 2026.

• Quarterly Profit After Tax fell 48.89% year-over-year to -$21.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$77.0 million (changed N/A YoY) and the FY2025 annual result came in at -$68.9 million, down 3.09% from the prior year.
• Profit After Tax rose to -$21.7 million in Q1 2026 per EVMN's latest filing, from -$28.3 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$12.5 million in Q3 2025 and bottomed at -$28.3 million in Q4 2025.
• The 3-year median for Profit After Tax is -$18.3 million (2024), against an average of -$18.9 million.
• The widest annual swing landed in 2025, when Profit After Tax increased 21.62%; it then slumped 48.89% in 2026.
• Tracing EVMN's Profit After Tax over 3 years: stood at -$20.7 million in 2024, then tumbled by 36.41% to -$28.3 million in 2025, then gained by 23.34% to -$21.7 million in 2026.
• Per Business Quant, the three latest EVMN Profit After Tax figures stand at -$21.7 million (Q1 2026), -$28.3 million (Q4 2025), and -$12.5 million (Q3 2025).

Peer Comparison